Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CMPX NASDAQ:CRDF NASDAQ:OPT NASDAQ:SVRA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$4.28+0.9%$3.38$1.27▼$4.40$586.32M1.481.85 million shs1.58 million shsCRDFCardiff Oncology$2.26+2.3%$2.20$1.90▼$5.64$147.02M1.62856,532 shs379,258 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$583.10M1.17N/A3,000 shsSVRASavara$3.41+1.2%$3.32$1.89▼$4.30$582.46M0.461.09 million shs1.35 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics+0.94%+16.62%+19.89%+43.62%+116.16%CRDFCardiff Oncology+2.26%+2.73%+10.24%-45.15%-14.07%OPTOpthea0.00%0.00%0.00%0.00%-33.53%SVRASavara+1.19%-1.45%-4.21%+48.91%-9.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCMPXCompass Therapeutics$4.28+0.9%$3.38$1.27▼$4.40$586.32M1.481.85 million shs1.58 million shsCRDFCardiff Oncology$2.26+2.3%$2.20$1.90▼$5.64$147.02M1.62856,532 shs379,258 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$583.10M1.17N/A3,000 shsSVRASavara$3.41+1.2%$3.32$1.89▼$4.30$582.46M0.461.09 million shs1.35 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCMPXCompass Therapeutics+0.94%+16.62%+19.89%+43.62%+116.16%CRDFCardiff Oncology+2.26%+2.73%+10.24%-45.15%-14.07%OPTOpthea0.00%0.00%0.00%0.00%-33.53%SVRASavara+1.19%-1.45%-4.21%+48.91%-9.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCMPXCompass Therapeutics 2.91Moderate Buy$13.10206.07% UpsideCRDFCardiff Oncology 2.50Moderate Buy$10.63370.13% UpsideOPTOpthea 2.00Hold$1.33-60.90% DownsideSVRASavara 2.57Moderate Buy$7.50119.94% UpsideCurrent Analyst Ratings BreakdownLatest CRDF, CMPX, OPT, and SVRA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CRDFCardiff OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/6/2025CMPXCompass TherapeuticsCompass PointSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$10.0010/6/2025CMPXCompass TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$10.009/27/2025CMPXCompass TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRDFCardiff OncologyWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OPTOptheaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SVRASavaraWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/9/2025SVRASavaraGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$8.00 ➝ $11.009/8/2025SVRASavaraOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$6.00 ➝ $8.00(Data available from 10/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCMPXCompass Therapeutics$850K696.28N/AN/A$0.91 per share4.70CRDFCardiff Oncology$680K221.11N/AN/A$1.86 per share1.22OPTOpthea$30K19,437.00N/AN/A($1.31) per share-2.60SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCMPXCompass Therapeutics-$49.38M-$0.45N/AN/AN/AN/A-53.11%-46.14%11/11/2025 (Estimated)CRDFCardiff Oncology-$45.43M-$0.87N/AN/AN/A-9,344.14%-77.94%-63.65%11/6/2025 (Estimated)OPTOpthea-$162.79MN/A0.00N/AN/AN/AN/AN/AN/ASVRASavara-$95.88M-$0.50N/AN/AN/AN/A-69.05%-54.84%11/11/2025 (Estimated)Latest CRDF, CMPX, OPT, and SVRA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025CMPXCompass Therapeutics-$0.14N/AN/AN/AN/AN/A11/11/2025Q3 2025SVRASavara-$0.13N/AN/AN/AN/AN/A11/6/2025Q3 2025CRDFCardiff Oncology-$0.20N/AN/AN/A$0.12 millionN/A8/13/2025Q1 2025SVRASavara-$0.12-$0.14-$0.02-$0.14N/AN/A8/11/2025Q2 2025CMPXCompass Therapeutics-$0.13-$0.14-$0.01-$0.14N/AN/A7/29/2025Q2 2025CRDFCardiff Oncology-$0.19-$0.21-$0.02-$0.21$0.11 million$0.12 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCMPXCompass TherapeuticsN/AN/AN/AN/AN/ACRDFCardiff OncologyN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCMPXCompass TherapeuticsN/A7.667.66CRDFCardiff OncologyN/A4.424.42OPTOptheaN/A0.220.22SVRASavara0.2511.0811.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCMPXCompass Therapeutics68.43%CRDFCardiff Oncology16.29%OPTOpthea55.95%SVRASavara87.93%Insider OwnershipCompanyInsider OwnershipCMPXCompass Therapeutics29.80%CRDFCardiff Oncology7.70%OPTOpthea3.20%SVRASavara5.13%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCMPXCompass Therapeutics20138.28 million97.08 millionNot OptionableCRDFCardiff Oncology2066.53 million61.40 millionOptionableOPTOpthea8171.00 million165.53 millionNot OptionableSVRASavara20172.84 million163.97 millionOptionableCRDF, CMPX, OPT, and SVRA HeadlinesRecent News About These CompaniesSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 13 at 5:55 PM | prnewswire.comSVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 13 at 4:59 PM | prnewswire.comSavara Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SVRAOctober 13 at 4:59 PM | prnewswire.comClass Action Filed Against Savara Inc. (SVRA) Seeking Recovery for Investors – Contact The Gross Law FirmOctober 13 at 4:00 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRAOctober 13 at 2:34 PM | prnewswire.comNovember 7, 2025 Deadline: Contact The Gross Law Firm to Join Class Action Suit Against SVRAOctober 13 at 9:00 AM | prnewswire.comSVRA INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 12 at 8:44 AM | globenewswire.comContact Levi & Korsinsky by November 7, 2025 to Join Class Action Against Savara Inc. (SVRA)October 11 at 7:46 PM | theglobeandmail.comLost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyOctober 11 at 7:46 PM | theglobeandmail.comSavara Inc. (SVRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud LawsuitOctober 10, 2025 | prnewswire.comSAVARA ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Savara, Inc. To Contact the Firm Before the November 7th Deadline Regarding the Filed Class Action LawsuitOctober 10, 2025 | globenewswire.comROSEN, GLOBAL INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action– SVRAOctober 10, 2025 | globenewswire.comSVRA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Savara Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 10, 2025 | globenewswire.comSavara Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - SVRAOctober 10, 2025 | prnewswire.comSHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SavaraOctober 9, 2025 | prnewswire.comShareholders that lost money on Savara Inc.(SVRA) Urged to Join Class Action – Contact Levi & Korsinsky to Learn MoreOctober 9, 2025 | globenewswire.comShareholders that lost money on Savara Inc.(SVRA) should contact The Gross Law Firm about pending Class Action - SVRAOctober 9, 2025 | prnewswire.comSavara: Back On Track With Upcoming APAP BLA FilingOctober 9, 2025 | seekingalpha.comSavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead ...October 9, 2025 | caledonianrecord.comCWeiss Ratings Reaffirms Sell (D-) Rating for Savara (NASDAQ:SVRA)October 9, 2025 | marketbeat.comSavara Inc. INVESTOR ALERT: Kirby McInerney LLP Reminds Savara Inc. Investors of Looming Lead Plaintiff Deadline in Class Action LawsuitOctober 8, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesMemes Are Back: Retail Investors Are Piling Into 3 Quantum StocksBy Dan Schmidt | September 29, 2025Azure Leads While AI Excitement Fuels Microsoft StockBy Chris Markoch | September 19, 20252 Ways to Trade Amazon Ahead of October’s Prime DayBy Sam Quirke | September 24, 2025Why Traders Are Doubling Down on SoundHound Stock After Big RallyBy Gabriel Osorio-Mazilli | September 25, 2025A Closer Look at D-Wave's Big Gains in September: More in Store?By Nathan Reiff | September 30, 2025CRDF, CMPX, OPT, and SVRA Company DescriptionsCompass Therapeutics NASDAQ:CMPX$4.28 +0.04 (+0.94%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$4.22 -0.06 (-1.29%) As of 05:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.Cardiff Oncology NASDAQ:CRDF$2.26 +0.05 (+2.26%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$2.27 +0.01 (+0.44%) As of 04:10 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 10/13/2025 03:30 PM EasternOpthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Savara NASDAQ:SVRA$3.41 +0.04 (+1.19%) Closing price 10/13/2025 04:00 PM EasternExtended Trading$3.41 0.00 (0.00%) As of 10/13/2025 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Levi Strauss Stock Set to Reach New Highs in 2026 Alphabet: The AI Powerhouse Driving Markets Into 2026 Is the Reddit-ChatGPT Love Affair Over? Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
